COHERUS BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.9 USD | -10.38% |
|
-16.30% | -42.94% |
| May. 09 | Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M | MT |
Presenter SpeechJason Gerberry (Analysts)Our last presentation slot of the Bank of America Ann...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
Calendar
2024-05-29
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.9
USD
Average target price
8.333
USD
Spread / Average Target
+338.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -42.94% | 218M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- CHRS Stock
- News Coherus BioSciences, Inc.
- Transcript : Coherus BioSciences, Inc. Presents at Bank of America 2022 Healthcare Conference, May-12-2022 12